

Accepted authors manuscript. Published in final edited form as: Journal of Cardiovascular Translational Research JCTR 2020 epub. Publisher DOI: 10.1007/s12265-020-09969-4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Facilitation through Aggrastat or cangrelor Bolus and infusion Over prasugrel: a multicenter randomized open-label trial in patients with ST-elevation myocardial infarction referred for primary percutaneous intervention (FABOLUS FASTER) Trial: Design and Rationale

Giuseppe Gargiulo^{1,2}, MD, PhD, Plinio Cirillo², MD, PhD, Michael Nagler³, MD, PhD, Pietro Minuz⁴, MD, Gianluca Campo^{5,6}, MD, PhD, Felice Gragnano¹, MD, Negar Manavifar¹, MD, Raffaele Piccolo², MD, PhD, Marisa Avvedimento², MD, Matteo Tebaldi⁵, MD, Andreas Wahl¹, MD, Lukas Hunziker¹, MD, Michael Billinger¹, MD, Dik Heg⁷, PhD, Stephan Windecker¹, MD, Marco Valgimigli¹, MD, PhD.

¹Department of Cardiology, Bern University Hospital, Bern, Switzerland

²Department of Advanced Biomedical Sciences, Federico II University of Naples, Naples, Italy

³University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Switzerland

⁴Department of Medicine, Unit of General Medicine for the Study and Treatment of Hypertensive Disease, University of Verona, Policlinico GB Rossi, Verona, Italy

⁵Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Cona FE, Italy

⁶Maria Cecilia Hospital, GVM Care & Research, Cotignola, RA, Italy

⁷Clinical Trials Unit (CTU) Bern, University of Bern, Bern, Switzerland

Subtitle: The FABOLUS FASTER Trial

Word count: 6100

Address for correspondence:

Prof. Marco Valgimigli, MD, PhD;
Bern University Hospital, CH-3010, Bern, Switzerland
Email: marco.valgimigli@insel.ch;
Phone: +41 31 632 96 53; Fax: +41 31 632 47 71

Abstract

1
2 Antithrombotic therapy is a critical component of the management of ST-elevation myocardial
3
4 infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Rapid
5
6 and profound inhibition of platelet reactivity has been shown to mitigate the ischemic risks and
7
8 improve myocardial salvage.
9
10

11 High residual platelet reactivity (HRPR) has been reported up to 4 or 6 hours after loading dose of
12
13 prasugrel or ticagrelor, therefore, multiple alternative strategies, including crushed or chewed oral
14
15 tablets or intravenous agents, have been investigated to provide a more rapid and sustained
16
17 inhibition of platelet function and bridge the initial treatment gap. The FABOLUS-FASTER is the
18
19 first investigator-initiated, multicentre, open-label, prospective, randomized study to directly
20
21 compare the pharmacodynamics effects of cangrelor, tirofiban, chewed or integer prasugrel. This
22
23 study will add new insights in the management of antiplatelet therapy in patients with STEMI
24
25 undergoing primary PCI and might be hypothesis-generating for future clinical trials in this field.
26
27
28
29
30
31 The trial is registered on clinicaltrials.gov NCT02978040, and EudraCT 2017-001065-24.
32
33
34
35

36 **Keywords:** primary PCI, cangrelor, tirofiban, prasugrel, platelet aggregation
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abbreviations

1
2 AAR=area at risk
3

4 AUC=area under the curve
5

6
7 ACS=acute coronary syndrome
8

9 ACT=activated clotting time
10

11 ADP=adenosine diphosphate
12

13 ATP=adenosine triphosphate
14

15
16 cMRI=magnetic resonance imaging
17

18
19 ECG=electrocardiogram
20

21 HPRP=high residual platelet reactivity
22

23
24 IPA=inhibition of platelet activity
25

26 LTA=light transmittance aggregometry
27

28 MS=myocardial salvage
29

30 MSI=myocardial salvage index
31

32
33 MVO=microvascular obstruction
34

35
36 PAM=prasugrel active metabolite
37

38
39 PCI=percutaneous coronary intervention
40

41 PD=pharmacodynamic
42

43 PK=pharmacokinetic
44

45
46 STEMI=ST-elevation myocardial infarction
47

48 UFH=unfractionated heparin
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

BACKGROUND

1
2 Antithrombotic therapy is crucial in the management of ST-elevation myocardial infarction
3
4 (STEMI) treated with primary percutaneous coronary intervention (PCI)[1-4]. Multiple pathways
5
6 are involved in platelet activation, adhesion, aggregation and fibrin synthesis; hence, several anti-
7
8 thrombotics including oral and/or parenteral anti-platelet and anticoagulation agents are to be
9
10 administered in the acute phase of STEMI[5,6]. The Facilitation through Aggrastat or cangrelor
11
12 Bolus and infusion Over prasugrel: a multicenter randomized open-label trial in patients with ST-
13
14 elevation myocardial infarction referred for primary percutaneous intervention (FABOLUS
15
16 FASTER) aims at investigating the acute pharmacodynamic effects of cangrelor, tirofiban or
17
18 prasugrel, administered at standard 60 mg loading dose as integer or chewed tablets, in STEMI
19
20 patients undergoing primary PCI.
21
22
23
24
25
26
27

Oral P2Y12 inhibitors

28
29 The combination of aspirin and oral inhibitors of ADP-activated platelet P2Y12 receptor such as
30
31 prasugrel or ticagrelor has been shown to reduce ischemic recurrences as compared to aspirin and
32
33 clopidogrel and represents the current standard of care[1-4]. However, high residual platelet
34
35 reactivity (HRPR) has been consistently reported up to 4 or 6 hours after prasugrel or ticagrelor
36
37 loading dose, with a large inter-individual variability[7-9]. The delayed onset and attenuated
38
39 antiplatelet effects have been attributed to impaired drug absorption resulting in reduced drug
40
41 bioavailability. Therefore, strategies to increase bioavailability of orally administered P2Y12
42
43 inhibitors have been further investigated in STEMI patients, including higher loading regimens,
44
45 which overall proved ineffective, or crushed/chewed tablets[10-16]. Two small-scale independent
46
47 studies suggested that crushed standard loading dose of ticagrelor or prasugrel can achieve more
48
49 pronounced platelet inhibition compared with standard whole tablets soon after drug
50
51 administration[13,14]. The MOJITO (Mashed Or Just Integral pill of TicagrelOr) trial found that in
52
53 82 patients a crushed standard loading dose of ticagrelor determined a more prominent platelet
54
55
56
57
58
59
60
61
62
63
64
65

1 inhibition (assessed with VerifyNow system) 1 hour after drug administration compared with
2 integer tablets[13]. Similarly, the CRUSH trial enrolled 52 STEMI patients undergoing primary PCI
3 and found that crushed prasugrel accelerated drug absorption, and thus, provided faster and greater
4 antiplatelet effects (demonstrated by VerifyNow and whole blood vasodilator-stimulated
5 phosphoprotein [VASP] assays) compared with integer tablets[14]. A pharmacokinetic analysis
6 supported the pharmacodynamic findings by showing that crushed as compared to integer prasugrel
7 was associated with faster drug absorption and higher plasma concentrations of prasugrel active
8 metabolite (PAM) at 30 min and 1 h but not at 2 h[14]. In the IPAAD-Tica (The inhibition of
9 platelet-aggregation after administration of three different ticagrelor formulations) 91 patients with
10 stable angina were randomly assigned to integer, crushed or chewed ticagrelor tablets and platelet
11 reactivity was assessed by VerifyNow 20 and 60 min after loading dose. Chewed ticagrelor was
12 associated with significantly reduced PRU values compared with crushed or integer tablets at both
13 20 and 60min, and crushed ticagrelor loading dose determined significantly lower PRU values
14 compared to integer tablets at 20 min but not at 60 min[16].
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **Tirofiban**

37 Tirofiban is a small molecule, nonpeptide tyrosine derivative which belongs to the class of
38 glycoprotein (GP) IIb/IIIa inhibitors (GPI) [6]. By inhibiting the binding of fibrinogen and von
39 Willebrand factor to the GP IIb/IIIa receptor on the surface of the platelet, GPIs are currently
40 considered the most potent inhibitors of platelet aggregation.
41
42
43
44
45
46
47

48 A dedicated meta-analysis focusing on the benefits and risks of this drug as compared to placebo
49 and abciximab has been published [17]. It included 31 studies and 20,006 patients (12,874
50 comparing tirofiban versus heparin plus placebo or bivalirudin alone, and 7,132 versus abciximab).
51 At 30-day, tirofiban significantly decreased mortality (OR=0.68 [0.54-0.86]; p=0.001), and death or
52 myocardial infarction (MI) (OR=0.69 [0.58-0.81]; p<0.001) when compared with placebo. This
53 benefit persisted at follow-up but was counterbalanced by a higher risk of minor bleedings or
54
55
56
57
58
59
60
61
62
63
64
65

1 thrombocytopenia. There was no difference between tirofiban and abciximab in 30-day mortality
2 (OR=0.90 [0.53, 1.54]; p=0.70), while in the overall group tirofiban trended to increase the
3
4 composite of death or MI (OR=1.18 [0.96, 1.45]; p=0.11), although this trend was not present at
5
6 medium-term follow-up or when assessing studies using the 25µ/kg bolus of tirofiban.
7

8
9 Current guidelines recommend the use of GPI, including tirofiban in selected situations[1-3].
10

11 In the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in
12 patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given
13
14 at loading dose) trial, 100 STEMI patients randomly received prasugrel 60 mg versus 25 µg/kg
15
16 tirofiban bolus with or without post-bolus 2-h infusion of tirofiban, with or without concomitant
17
18 prasugrel. Inhibition of platelet activity (IPA) at light transmittance aggregometry was performed
19
20 throughout 24 h. Compared with prasugrel-treated patients, those in the tirofiban group had a
21
22 significantly higher IPA to 20 µmol/l ADP stimulation as (87±31 vs. 36±35, p<0.0001) at 30 min.
23
24 Similarly, the degree of platelet inhibition remained suboptimal for at least 2h in prasugrel-treated
25
26 patients. When concomitant clopidogrel was given, the post-bolus tirofiban infusion was necessary
27
28 to maintain a high level of IPA beyond 1h. Conversely, the bolus-only tirofiban and concomitant
29
30 prasugrel were associated with the higher and more consistent IPA levels after both ADP and
31
32 thrombin receptor-activating peptide stimuli compared with either therapy alone. There is currently
33
34 no head to head comparison between tirofiban and cangrelor on the degree of platelet inhibition.
35
36
37
38
39
40
41
42
43
44
45

46 **Cangrelor**

47 Cangrelor, is an intravenous reversible inhibitor of ADP-induced platelet aggregation. In most
48
49 recent guidelines it is to be considered in P2Y12 inhibitor-naïve patients undergoing PCI, including
50
51 primary PCI, with the same class of recommendation attributed to GPI [2]. Cangrelor is an ATP
52
53 analogue and it is meant to achieve almost complete and immediate inhibition of ADP-induced
54
55 platelet aggregation when administered as a bolus plus infusion. The plasma half-life is
56
57 approximately 3 to 5 minutes and platelet function is entirely restored within 1 hour after cessation
58
59
60
61
62
63
64
65

1 of infusion[6,18-20]. After animal studies, this agent was tested in humans. In a study of 39 patients
2 with unstable angina or non-Q wave myocardial infarction, who were receiving aspirin and heparin,
3
4 cangrelor (initially identified as AR-C69931MX) was administered intravenously with stepped dose
5
6 increments over 3 h to a plateau at either 2 µg/kg/min for 21 h (Part 1; n=12) or up to 69 h (Part 2;
7
8 n=13) or 4 µg/kg/min for up to 69 h (Part 3: n=14)[21]. This study assessed safety parameters,
9
10 platelet aggregation (PA) induced by ADP 3 µmol/L (impedance aggregometry), bleeding time
11
12 (BT) and cangrelor plasma concentrations. In patients completing the study (n=33) cangrelor was
13
14 well tolerated. At 30-day no deaths or serious adverse events occurred, but trivial bleeding (56%)
15
16 was frequent. Mean IPA was 36.2±39.2, 20.7±25.9 and 40.7±36.7% at 1 h post-infusion,, and
17
18 96.0±8.6, 94.9±14.4 and 98.7±2.1% at 24 h, for Parts 1, 2 and 3 respectively. Platelet aggregation
19
20 test was based on the whole blood impedance aggregometry (Chronolog), and the stimulation was
21
22 done with ADP 3 µmol/L. In a subsequent study, clopidogrel moderately inhibited platelet P2Y12
23
24 receptor activation while cangrelor induced a substantially greater P2Y12 receptor inhibition[20]. In
25
26 this study, however, the 13 patients with acute coronary syndromes (ACS) receiving cangrelor
27
28 (Group 1; stepped dose increments of cangrelor achieving a plateau after 3 h of 2 or 4 µg/kg per
29
30 min in 8 and 5 patients, respectively), and 8 patients undergoing coronary stenting receiving
31
32 clopidogrel (Group 2, 300 mg loading dose followed from 75 mg daily) were studied using a whole
33
34 blood single-platelet counting aggregation assay that was collected at 30 min and 21h from infusion
35
36 (and 69h in some patients) onset for cangrelor and 4-7 days for clopidogrel. An initial experience of
37
38 cangrelor in patients undergoing PCI was obtained in a 2-part randomized trial comparing different
39
40 dosages of cangrelor (1 or 2 or 4 µg/kg/min for 18-24h) with placebo in 200 patients and then
41
42 comparing cangrelor (4 µg/kg/min for 18-24h) vs abciximab (0.25 mg/kg bolus followed by 0.125
43
44 µg/kg per minute up to 10 µg per minute for up to 12h) in 199 patients[22]. Cangrelor was
45
46 associated with an acceptable risk of bleeding and adverse cardiac events, and less prolongation of
47
48 bleeding time compared with abciximab, but this study did not include any pharmacodynamic
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 analysis. The CHAMPION-PLATFORM and CHAMPION-PCI trials compared cangrelor with
2 placebo in clopidogrel treated patients with ACS or stable CAD undergoing PCI[23,24]. In both
3 trials, cangrelor was administered with an intravenous bolus of 30 µg/kg followed by infusion of 4
4 µg/kg/min for at least 2h or until the conclusion of the index procedure, whichever was longer (at
5 the clinician's discretion, the infusion could be continued for 4h). In these trials, the enrolment was
6 stopped when an interim analysis concluded that the trials would be unlikely to show superiority for
7 the primary endpoint. The platelet function substudy of these 2 trials tested the pharmacodynamic
8 effects of cangrelor vs clopidogrel and was the largest pharmacodynamic experience with cangrelor
9 up to that time[19]. This study demonstrated the potent P2Y12 receptor inhibitory effects of
10 cangrelor, as well as its rapid onset/offset of action based on VerifyNow analysis in 167 patients (84
11 treated with cangrelor + clopidogrel and 83 treated with placebo + clopidogrel), mainly from
12 CHAMPION-PCI trial. Moreover, this study included LTA assessment in 44 patients showing
13 significantly greater inhibition in cangrelor-treated patients (LTA ADP 20 µM median 20.0 % vs
14 69.5 %, p<0.001; and ADP 5 µM median: 2.5 % vs 49.0 %, p<0.001), but these values referred to
15 the final (after 6 min) platelet aggregation not the max aggregation. An additional study tested the
16 PK and PD effects of cangrelor bolus and infusion at the regimen currently used[18]. Twenty-two
17 healthy volunteers were randomly assigned to 15-µg/kg bolus followed by a 2-µg/kg/min infusion
18 (n=12) or 30-µg/kg bolus followed by a 4-µg/kg/min infusion (n=10) and the infusion was
19 continued for 60 minutes. The higher dose provided more consistent and pronounced inhibition on
20 ADP-induced P-selectin expression, but no significant differences were observed between the 2
21 regimens in terms of platelet aggregation or time to recovery of platelet function. It is important to
22 note that, however, this study was conducted in healthy volunteers, and again platelet aggregation
23 was assessed by a whole blood test but not LTA.

24 To date, there are limited data on the effects of cangrelor used in combination with oral P2Y12
25 inhibitors in patients undergoing primary PCI and questions have emerged on the potential for drug-
26 drug interactions during the transition from cangrelor to oral P2Y12 inhibitors. Indeed, it is

1 generally recommended that clopidogrel and prasugrel should be administered at the end of the
2 cangrelor infusion, while for ticagrelor the simultaneous administration could not be an issue,
3
4 however, evidence on these interactions are still limited[25]. In the recent CANTIC study, 50
5
6 STEMI patients undergoing primary PCI were randomly assigned to cangrelor or placebo (bolus
7
8 followed by 2h infusion)[26]. All patients received crushed tablets of ticagrelor 180-mg loading
9
10 dose at the time of cangrelor/placebo bolus administration. Pharmacodynamic analyses were
11
12 performed at 8 time points (expressed as P2Y12 reaction units by VerifyNow and platelet reactivity
13
14 index by vasodilator-stimulated phosphoprotein). This study supported the efficacy of cangrelor in
15
16 bridging the gap of platelet inhibition associated with the use of oral P2Y12 inhibition induced by
17
18 ticagrelor, without any apparent drug-drug interaction[26].
19
20
21
22
23
24
25

26 **STUDY RATIONALE**

27
28 The use of an intravenous antiplatelet agent including a parenteral P2Y12 inhibitor such as
29
30 cangrelor or a GPI, such as tirofiban, on top of oral therapy with aspirin and a P2Y12 inhibitor
31
32 confers the benefit of a more rapid and stronger antagonism of platelet reactivity, thus bridging the
33
34 initial gap in platelet inhibition associated with the use of oral P2Y12 inhibitors in STEMI patients.
35
36 The association of parenteral and oral antiplatelet agents might therefore mitigate the increased risk
37
38 of early thrombotic complications and improve myocardial salvage conferred by mechanical
39
40 revascularisation. However, the association of multiple potent antithrombotics increases the
41
42 bleeding risk by a magnitude that is depending on patient characteristics and procedural features.
43
44 Cangrelor was shown in a propensity-matched study to be associated to less bleeding risk and
45
46 comparable ischemic protection as compared to GPI administered at standard prolonged post-bolus
47
48 infusion [27]. Whether this postulated differential safety profile of these two agents comes from a
49
50 different degree of ADP-induced inhibition of platelet aggregation, the inherent mechanism of
51
52 action (i.e. ADP as opposed to GP antagonism) or overall duration of treatment (i.e. 2h versus \geq 12h
53
54 infusion) remains speculative.
55
56
57
58
59
60
61
62
63
64
65

1 The comparative effectiveness of cangrelor and tirofiban on-label regimens in inhibiting platelet
2 reactivity remains unknown. Similarly, it remains unclear if the standard loading dose of prasugrel,
3
4 when chewed, might mitigate the absorption delay observed with all oral P2Y12 inhibitors in
5
6 STEMI patients and therefore potentially reduce the need for concomitant parenteral antiplatelet
7
8 agents.
9
10

11 12 13 14 **METHODS**

15 16 17 **Study design and patient population**

18
19 The FABOLUS FASTER is an investigator-initiated, multicentre, open-label, randomized study.

20
21 The study is registered on clinicaltrials.gov NCT02978040, and EudraCT 2017-001065-24.

22
23 The purpose of this study is to compare the efficacy with respect to the inhibition of platelet
24
25 aggregation of cangrelor, tirofiban, or prasugrel, administered as integer or chewed tablets in
26
27 STEMI patients undergoing primary PCI. The study design and flow-chart are summarised in
28
29

30 31 **Figures 1 and 2.**

32
33 Patients undergoing primary PCI due to suspected STEMI are screened at admission and, after
34
35 adequate explanation, those consenting are enrolled in the study by dedicated staff previously
36
37 identified at each participating centre. No screening log is mandated by study and only randomized
38
39 patients with written consent are to be reported. Eligibility criteria are reported in **Table 1**. Briefly,
40
41 adult patients presenting with STEMI and referred for primary PCI within 12 hours (or 24h if
42
43 ongoing ischemia is demonstrated) will be enrolled. Key exclusion criteria are: unconsciousness or
44
45 other conditions that make the patient incapable of providing informed consent and receiving oral
46
47 loading dose of prasugrel, bleeding diathesis, recent administration of fibrinolytics or GPI or P2Y12
48
49 inhibitors or cangrelor, recent major surgery or bleeding, chronic dialysis, previous intracranial
50
51 haemorrhage, previous stroke or recent TIA, known hypersensitivity to study drugs, chronic oral
52
53 anticoagulant therapy, pregnancy or breastfeeding, limited life expectancy.
54
55
56
57
58
59
60
61
62
63
64
65

1 Patients are being randomly assigned in a 1:1:1 fashion to tirofiban (≥ 40 patients, bolus + 2 hour
2 infusion, followed by prasugrel at 60 mg loading dose at the time of infusion discontinuation),
3
4 cangrelor (≥ 40 patients, bolus + 2 hour infusion, followed by prasugrel at 60 mg loading dose at the
5
6 time of infusion discontinuation) or prasugrel 60 mg (≥ 40 patients, at the beginning of the PCI,
7
8 administered as either integer or chewed tablets). Patients assigned to the prasugrel arm undergo an
9
10 immediate 1:1 sub-randomization to either chewed or integer oral loading dose of prasugrel.
11
12 Randomization is concealed and stratified according to centre and to time from onset of symptoms
13
14 to PCI (<3 hours, 3-6 hours, >6 hours) with blocks of 3 or 6 alternating randomly for the first
15
16 randomization, and stratified according to centre with blocks of 2 or 4 alternating randomly for the
17
18 second randomization, within the electronic data capture system ICE provided by Advice Pharma
19
20 Group (<https://advicepharma.com/en/technologies/ice/>).
21
22
23
24
25
26
27
28

29 **Medications and procedures**

30
31 All patients have to receive aspirin before primary PCI (150-300 mg orally or 80-150 mg i.v., then
32
33 81-325 mg daily). Patients allocated to Cangrelor receive the on-label regimen in terms of bolus of
34
35 30 $\mu\text{g}/\text{Kg}$ followed by infusion at 4 $\mu\text{g}/\text{Kg}/\text{min}$ for 2 h (or to the end of PCI). Tirofiban will be
36
37 administered according to the single high dose bolus (SHDB) of 25 $\mu\text{g}/\text{Kg}$ followed by infusion at
38
39 0.15 $\mu\text{g}/\text{Kg}/\text{min}$ for 2 h (or to the end of PCI) (or an infusion rate of 0.075 $\mu\text{g}/\text{Kg}/\text{min}$ for patients
40
41 with known creatinine clearance <30 ml/min). At the end of infusion, oral prasugrel at a loading
42
43 dose of 60 mg is to be administered as integer tablets, followed by 10 mg daily (or 5 mg daily if
44
45 body weight < 60 kg or age > 75 years old) in accordance to the instructions for use and
46
47 international guidelines. In the prasugrel arm, no intravenous anti-platelet drug is to be
48
49 administered. Patients randomized to prasugrel receive either integer or chewed prasugrel at an
50
51 identical loading dose of 60 mg, then 10 mg daily (or 5 mg daily if body weight < 60 kg or age > 75
52
53 years old). In the chewed prasugrel arm, patients are instructed to chew pills for at least 10–15 s
54
55 followed by oral administration of 150 mL of water as previously described [16].
56
57
58
59
60
61
62
63
64
65

1 Anticoagulation is to be achieved with concomitant unfractionated heparin (UFH) or enoxaparin
2 whereas bivalirudin is not allowed to avoid potential confounding effects. UFH is to be
3
4 administrated as bolus of 50-70 UI/Kg in the two parenteral antiplatelet arms or at 70-100 UI/Kg
5
6 bolus in the prasugrel arm, then adjusted with additional adjunctive boluses in order to achieve an
7
8 activated clotting time (ACT) of at least 250s during the procedure. UFH administration after the
9
10 end of the procedure is discouraged unless clinically indicated.
11
12

13
14 Blood samples are obtained at randomization and before the administration of study drug (baseline)
15
16 and then, counting from drug bolus termination (tirofiban and cangrelor arms) or oral loading dose
17
18 of prasugrel, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours and between 4 to 6 hours thereafter.
19
20 ECG is recorded before and immediately after PCI and 90 minutes thereafter, as well as at
21
22 discharge. Patients providing consent to participate to the imaging sub-study, will undergo cardiac
23
24 magnetic resonance imaging (cMRI) at 3 ± 1 days and 5 ± 1 months. Clinical data collection (vital
25
26 signs, medications, clinical events and serious adverse events) is collected throughout 30 days.
27
28
29
30
31
32
33

34 **Pharmacodynamic analysis**

35
36 LTA analysis remains the gold standard of platelet function evaluation[28], and is being performed
37
38 as previously described[9]. Briefly, at each participating centre, blood samples anticoagulated with
39
40 0.129 mol/l sodium citrate will be collected. Platelet-rich plasma, obtained by centrifuging whole
41
42 blood for 10 min at 70g, will be stimulated with 5 and 20 $\mu\text{mol/l}$ ADP and 5 and 15 $\mu\text{mol/l}$
43
44 thrombin receptor agonist peptide (TRAP), and aggregation will be assessed using a light
45
46 transmission aggregometer. The 100% line will be set using platelet-poor plasma and the 0 baseline
47
48 established with platelet-rich plasma (adjusted from $18\times 10^9/l$ up to $30\times 10^9/l$). Platelet aggregation is
49
50 being evaluated considering the maximal percentage of platelet aggregation in response to stimulus
51
52 (Agg_{max}). The percentage of late platelet aggregation (Agg_{late}) is also being collected for further
53
54 analyses.
55
56
57
58
59
60
61
62
63
64
65

1 Multiple electrode aggregometry (Multiplate, Roche Diagnostics, Switzerland) is being performed
2 as previously described[29] by using hirudin-anticoagulated whole blood samples. Blood will be
3
4 diluted with saline and then stimulated with ADP and TRAP reagents. After 1:2 dilution of whole
5
6 blood with 0.9% NaCl solution and stirring for 3 min in the test cuvettes at 37°C, ADP, and TRAP
7
8 stimulation will be added and platelet aggregation will be continuously recorded for 6 minutes. This
9
10 measurement simulates platelet adhesion, activation, and aggregation on a metal surface during
11
12 continuous stirring in an ex vivo setting, mimicking the development of stent thrombosis upon
13
14 platelet activation. Changes in impedance are plotted over time resulting in an aggregation curve,
15
16 similarly to LTA, and the efficacy of platelet inhibition is expressed with the area-under-the
17
18 aggregation-curve (AUC) value.
19
20
21
22
23
24
25

26 **Pharmacokinetic analysis**

27
28 A pharmacokinetic analysis will be performed within the Prasugrel arm in order to compare integer
29
30 versus chewed Prasugrel administration. Prasugrel Active Metabolites (PAM) will be measured at
31
32 each time point under the secondary hypothesis that chewed as compared to integer prasugrel will
33
34 lead to higher PAM bioavailability at 30 minutes (and other time points: 15min to 4-6h hours).
35
36
37

38 Blood samples for the determination of PAM plasma concentration will be collected into pre-cooled
39
40 EDTA tubes at the established time points (baseline, 15 min, 30 min, 1h, 2h, 3h and 4-6h) and will
41
42 be treated with 25µl of 500 mM 3'-methoxyphenacyl bromide in acetonitrile within 30 s of
43
44 collection to derivatize and stabilize the PAM as previously described[14,30]. Centrifugation of the
45
46 sample will be performed within 30 minutes (2800 rpm for 15 min at 4°C), and plasma samples
47
48 prepared from these blood samples will be stored at -20/-80°C in polypropylene tubes until they
49
50 will be shipped to the central laboratory at University Hospital of Verona (LURM) for analysis.
51
52
53

54 Plasma concentrations of PAM will be determined using validated liquid chromatography methods
55
56 and tandem mass spectrometric detection.
57
58
59
60
61
62
63
64
65

Endpoints

The primary endpoint is the percentage of inhibition of platelet activity (IPA) assessed with light transmission aggregometry (LTA) in platelet-rich plasma after the addition of ADP 20 µmol/l at 30 minutes from drug administration (bolus or oral loading dose). Percentage IPA is defined as $100\% * (\text{baseline platelet aggregation} - \text{at time } t \text{ platelet aggregation}) / \text{baseline platelet aggregation}$ [9]. Baseline is at time 0 minutes just before drug administration, follow-up measurements are at time 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours and 4 to 6 hours since drug administration.

Secondary endpoints include LTA using TRAP at 5 and 15 µmol/l, as well as ADP at 5 µmol/l at all different time points and up to 6 hours and ADP at 20 µmol/l at time points before and later than 30 minutes (15 minutes, 1h, 2h, 3h, 4-6h).

Other secondary endpoints will include the residual platelet reactivity assessed with Multiplate® technology (AUC at impedance aggregometry Multiplate® Electrode Aggregometry in whole blood) at all time frames and after ADP and TRAP as agonists.

For the pharmacokinetic analysis, the time for the maximum plasma concentration (T_{max}), maximum observed plasma concentration (C_{max}), and the area under the plasma concentration versus time curve from time 0 to the last measurable concentration (AUC_{0-t}) will be calculated.

Moreover, to explore early exposure to PAM, AUC from time 0 to 2 h (AUC₀₋₂) will be also calculated.

Adverse clinical ischemic and bleeding events at 48 hours and 30 days will be also collected and include: death, cardiac death, non-fatal myocardial infarction, non-fatal stroke, transient ischemic attack, urgent target vessel revascularization, unplanned revascularization, definite/probable stent thrombosis, bleeding events, net adverse clinical event.

Other endpoints will be analysed for the pre-specified substudies.

Sample size and statistics

1 The Clinical Trial Unit of Bern provides statistical oversight and guidance. The total number of
2 patients with primary endpoint assessment is 120, of whom at least 40 patients in the tirofiban
3
4 group, at least 40 patients in the cangrelor group, and at least 40 patients in the prasugrel group (of
5
6 which at least 20 integer and at least 20 chewed tablets).
7

8
9 Sample size is calculated to state the non-inferiority of cangrelor compared with tirofiban,
10
11 superiority of both tirofiban and cangrelor compared with chewed prasugrel and to show the
12
13 superiority of chewed prasugrel as compared to integer prasugrel.
14
15

16
17 The sample size was determined following these considerations, three primary non-inferiority tests
18
19 each with alpha of 0.05/3 tests = 0.016 and one additional test also with alpha of 0.016 for
20
21 consistency (chewed prasugrel vs integer prasugrel):
22

23
24 Assuming %IPA with 20 $\mu\text{mol/l}$ ADP at 30 minutes from randomization of at least 94% with i.v.
25
26 antiplatelet therapy, with a standard deviation of 8%, a non-inferiority margin of 9%, with an alpha
27
28 of 0.016, 40 patients per group will give 99% of power to show non-inferiority of cangrelor
29
30 compared to tirofiban. If non-inferiority of cangrelor will not be met, then the superiority of
31
32 tirofiban over cangrelor will be tested (pre-specified secondary endpoint).
33
34

35
36 Assuming %IPA with 20 $\mu\text{mol/l}$ ADP at 30 minutes of 55% with chewed prasugrel, with a standard
37
38 deviation of 24% and an alpha of 0.016, this study will have 100% of power to show both
39
40 superiority of Tirofiban (n=40) as compared to chewed Prasugrel (n=20) and superiority of
41
42 Cangrelor (n=40) as compared to chewed Prasugrel (n=20).
43
44

45
46 Assuming %IPA with 20 $\mu\text{mol/l}$ ADP at 30 minutes from randomization of 55% with chewed
47
48 prasugrel, with a standard deviation of 24% and an alpha of 0.016, 20 patients per group will give
49
50 82% of power to show superiority of chewed Prasugrel compared with integer Prasugrel.
51

52
53 These assumptions were largely based on previous evidence[9].
54

55
56 The pairwise mean difference in platelet inhibition (difference in %IPA) will be estimated and
57
58 reported with the 95% confidence intervals (Cangrelor vs Tirofiban, Cangrelor vs chewed
59
60 Prasugrel, Tirofiban vs chewed Prasugrel; based on using mixed models - including data on all
61
62
63
64
65

1 time-points since PCI, random effects of site and patient as appropriate), non-inferiority will be
2 tested using a z-test. Superiority tests will be conducted on platelet activity (% of IPA at LTA or
3
4 AUC unit at Multiplate, as continuous variables, random effects of site and patient as appropriate)
5
6 using mixed models (including data on all time-points since PCI) with Bonferroni post-hoc test.
7
8 Mixed models will use the appropriate link function according to the type of primary or secondary
9
10 endpoints measured (continuous, binary) and adjust for time-point (minutes to hours since PCI) and
11
12 the interaction between randomized arm and time-point, random effects added of site and patient as
13
14 appropriate. Rate of events will be compared with χ^2 test and hazard ratios calculated with Cox-
15
16 proportional-hazard model.
17
18
19
20
21
22
23

24 **Pre-specified substudies**

25
26 A pre-specified cMRI substudy will be performed in all patients providing consent to this additional
27
28 study procedure. cMRI will be performed as previously described[31,32]. The relationship with all
29
30 MRI parameters and platelet inhibition at each time point is to be explored. The primary cMRI
31
32 endpoints are the Myocardial salvage Index (MSI) which is defined as Myocardial Salvage/Area at
33
34 risk (MS/AAR) and the extent of intramyocardial haemorrhage. Many other secondary endpoints
35
36 will be analysed, including microvascular obstruction (MVO), and infarct size. Among the pre-
37
38 specified sub-analyses, we will explore the relationship between presence and extent of
39
40 intramyocardial haemorrhage and allocated treatment, degree of platelet inhibition, and time to
41
42 presentation.
43
44
45
46
47

48 An ECG/Angio substudy will investigate the impact of randomized treatment strategy on
49
50 electrocardiographic and angiographic parameters. Anonymized ECGs and angiographies will be
51
52 collected and analysed by a core-lab blinded to treatment strategy. Multiple parameters will be
53
54 extracted and compared among the groups and associated with platelet reactivity. ECG analysis will
55
56 be performed as previously described[33].
57
58
59
60
61
62
63
64
65

1 A PK/PD substudy will be also performed to explore the role of prasugrel inactive metabolite R-
2 95913 and its derivatized active metabolite (R-138727, PAM) and their relationship with PD
3
4 profiles. According to the kinetics profile, the threshold exposure that is required to determine a
5
6 meaningful pharmacodynamic response in platelets will be tentatively defined. To this aim, separate
7
8 and cumulative analysis of kinetics data deriving from each time point and any single patients will
9
10 be considered along with the maximum platelet response in ADP-induced platelet aggregation,
11
12 irrespectively of timing of blood sample collection. Time to response, threshold response, and
13
14 maximum response will be considered.
15
16

17
18 A cost-effectiveness analysis will be carried out by inputting direct and indirect costs in relation to
19
20 outcomes assessed both in terms of clinical events, surrogate markers of outcomes, such as ST-
21
22 segment elevation resolution or infarct size at MRI as well with respect to degree of platelet
23
24 inhibition.
25
26
27
28
29
30

31 **CLINICAL SIGNIFICANCE AND TRANSLATIONAL OUTLOOK**

32

33
34 Ischaemic heart disease is the single most common cause of death worldwide and its frequency is
35
36 increasing. STEMI remains frequent and is associated with substantial rates of mortality. In the last
37
38 years, there was a fall in acute and long-term mortality following STEMI in parallel with greater
39
40 use of reperfusion therapy, PCI, modern antithrombotic therapy, and secondary prevention.
41
42

43
44 However, mortality in STEMI patients remains between 4-12% in-hospital and 10% at 1-year
45
46 follow-up. Primary PCI is the standard of treatment of almost all STEMI patients and all patients
47
48 receive DAPT, a combination of aspirin and an oral P2Y12 inhibitor. There is still limited evidence
49
50 with respect to when the oral P2Y12 inhibitor should be initiated in STEMI patients and the only
51
52 randomized trial testing pretreatment in these patients with ticagrelor did not show advantages of
53
54 this strategy compared with administration at the time of PCI. Oral P2Y12 inhibitors are associated
55
56 to delay in the onset of effect in STEMI patients undergoing primary PCI. Therefore, intravenous
57
58 antiplatelet agents might be important in these patients to cover the initial gap in platelet inhibition
59
60
61
62
63
64
65

1 and help preventing the increased risk of early thrombotic complications. The FABOLUS FASTER
2 study is the first to directly compare the new intravenous P2Y12 inhibitor cangrelor with the
3
4 intravenous GPI tirofiban and the standard oral P2Y12 inhibitor prasugrel. Moreover, this study will
5
6 provide additional pharmacokinetic and pharmacodynamic data on the oral assumption of prasugrel
7
8 through chewed or standard intake of pills that could also be relevant to accelerate the absorption
9
10 and effect of this drug. The study findings will add new relevant insights in the management of
11
12 antiplatelet therapy in patients with STEMI undergoing primary PCI and might be also hypothesis-
13
14 generating for future trials in this field.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 **Funding:** This study is an Investigator-Initiated Trial supported by a grant to the institution
3 (Inselspital, University of Bern) from Medicure Inc, 2-1250 Waverley Street, Winnipeg, Manitoba,
4 CANADA R3T 6C6.
5

6 **Compliance with Ethical Standards**

7
8
9 **Ethics Approval:** The study was approved by the local Ethics Committees (“Kantonale
10 Ethikkommission Bern (KEK)” for Bern, Switzerland; “Comitato Etico Università Federico II” for
11 Naples and “Comitato Etico Area Vasta Emilia Centro - AVEC” for Ferrara, Italy) and the Italian
12 Agency of the Drug (AIFA).
13
14
15
16

17
18
19 **Human Subjects/Informed Consent Statement:** All procedures followed are in accordance with
20 the ethical standards of the responsible committee on human experimentation (institutional and
21 national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent is
22 obtained from all patients previous to being included in the study.
23
24
25
26
27
28

29 **Conflict of interest:**

30
31
32
33
34 FG reports research grant support from the European Society of Cardiology (ESC Research grant).

35
36 SW reports research and educational grants from Abbott, Amgen, Bayer, BMS, Boston Scientific,
37 Biotronik, CSL Behring, Edwards Lifesciences, Medtronic, Polares and Sinomed, outside the
38 submitted work.
39

40
41
42
43 MV reports grants and personal fees from Abbott, Alvimedica, Amgen, Bayer, Bristol-Myers
44 Squibb SA, Coreflow, Daiichi Sankyo, Vifor, Idorsia, Terumo, iVascular and AstraZeneca, outside
45 the submitted work.
46
47
48

49
50
51 Other authors have nothing to disclose.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

REFERENCES

1. Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., et al. (2018). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*, 39(2), 119-177, doi:10.1093/eurheartj/ehx393.
2. Neumann, F. J., Sousa-Uva, M., Ahlsson, A., Alfonso, F., Banning, A. P., Benedetto, U., et al. (2019). 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*, 40(2), 87-165, doi:10.1093/eurheartj/ehy394.
3. Valgimigli, M., Bueno, H., Byrne, R. A., Collet, J. P., Costa, F., Jeppsson, A., et al. (2018). 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J*, 39(3), 213-260, doi:10.1093/eurheartj/ehx419.
4. Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., et al. (2016). 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *J Am Coll Cardiol*, 67(10), 1235-1250, doi:10.1016/j.jacc.2015.10.005.
5. Davi, G., & Patrono, C. (2007). Platelet activation and atherothrombosis. *N Engl J Med*, 357(24), 2482-2494, doi:10.1056/NEJMra071014.
6. Gargiulo, G., Moschovitis, A., Windecker, S., & Valgimigli, M. (2016). Developing drugs for use before, during and soon after percutaneous coronary intervention. *Expert Opin Pharmacother*, 17(6), 803-818, doi:10.1517/14656566.2016.1145666.
7. Alexopoulos, D., Xanthopoulou, I., Gkizas, V., Kassimis, G., Theodoropoulos, K. C., Makris, G., et al. (2012). Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. *Circ Cardiovasc Interv*, 5(6), 797-804, doi:10.1161/CIRCINTERVENTIONS.112.972323.
8. Parodi, G., Valenti, R., Bellandi, B., Migliorini, A., Marcucci, R., Comito, V., et al. (2013). Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. *J Am Coll Cardiol*, 61(15), 1601-1606, doi:10.1016/j.jacc.2013.01.024.
9. Valgimigli, M., Tebaldi, M., Campo, G., Gambetti, S., Bristot, L., Monti, M., et al. (2012). Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. *JACC Cardiovasc Interv*, 5(3), 268-277, doi:10.1016/j.jcin.2012.01.006.
10. Alexopoulos, D., Barampoutis, N., Gkizas, V., Vogiatzi, C., Tsigkas, G., Koutsogiannis, N., et al. (2016). Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study. *Clin Pharmacokinet*, 55(3), 359-367, doi:10.1007/s40262-015-0320-0.
11. Asher, E., Frydman, S., Katz, M., Regev, E., Sabbag, A., Mazin, I., et al. (2017). Chewing versus Swallowing Ticagrelor to Accelerate Platelet Inhibition in Acute Coronary Syndrome - the CHEERS study. For The PLATIS (Platelets and Thrombosis in Sheba) Study Group. *Thromb Haemost*, 117(4), 727-733, doi:10.1160/TH16-09-0728.

12. Asher, E., Tal, S., Mazin, I., Abu-Much, A., Sabbag, A., Katz, M., et al. (2017). Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial. *JAMA Cardiol*, 2(12), 1380-1384, doi:10.1001/jamacardio.2017.3868.
13. Parodi, G., Xanthopoulou, I., Bellandi, B., Gkizas, V., Valenti, R., Karanikas, S., et al. (2015). Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. *J Am Coll Cardiol*, 65(5), 511-512, doi:10.1016/j.jacc.2014.08.056.
14. Rollini, F., Franchi, F., Hu, J., Kureti, M., Aggarwal, N., Durairaj, A., et al. (2016). Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study. *J Am Coll Cardiol*, 67(17), 1994-2004, doi:10.1016/j.jacc.2016.02.045.
15. Serenelli, M., Pavasini, R., Vitali, F., Tonet, E., Bilotta, F., Parodi, G., et al. (2019). Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: Systematic review and meta-analysis. *J Thromb Haemost*, 17(6), 944-950, doi:10.1111/jth.14434.
16. Venetsanos, D., Sederholm Lawesson, S., Swahn, E., & Alfredsson, J. (2017). Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: The inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. *Thromb Res*, 149, 88-94, doi:10.1016/j.thromres.2016.10.013.
17. Valgimigli, M., Biondi-Zoccai, G., Tebaldi, M., van't Hof, A. W., Campo, G., Hamm, C., et al. (2010). Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. *Eur Heart J*, 31(1), 35-49, doi:10.1093/eurheartj/ehp376.
18. Akers, W. S., Oh, J. J., Oestreich, J. H., Ferraris, S., Wethington, M., & Steinhubl, S. R. (2010). Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. *J Clin Pharmacol*, 50(1), 27-35, doi:10.1177/0091270009344986.
19. Angiolillo, D. J., Schneider, D. J., Bhatt, D. L., French, W. J., Price, M. J., Saucedo, J. F., et al. (2012). Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. *J Thromb Thrombolysis*, 34(1), 44-55, doi:10.1007/s11239-012-0737-3.
20. Storey, R. F., Wilcox, R. G., & Heptinstall, S. (2002). Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. *Platelets*, 13(7), 407-413, doi:10.1080/0953710021000024402.
21. Storey, R. F., Oldroyd, K. G., & Wilcox, R. G. (2001). Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. *Thromb Haemost*, 85(3), 401-407.
22. Greenbaum, A. B., Grines, C. L., Bittl, J. A., Becker, R. C., Kereiakes, D. J., Gilchrist, I. C., et al. (2006). Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. *Am Heart J*, 151(3), 689 e681-689 e610, doi:10.1016/j.ahj.2005.11.014.
23. Bhatt, D. L., Lincoff, A. M., Gibson, C. M., Stone, G. W., McNulty, S., Montalescot, G., et al. (2009). Intravenous platelet blockade with cangrelor during PCI. *N Engl J Med*, 361(24), 2330-2341, doi:10.1056/NEJMoa0908629.
24. Harrington, R. A., Stone, G. W., McNulty, S., White, H. D., Lincoff, A. M., Gibson, C. M., et al. (2009). Platelet inhibition with cangrelor in patients undergoing PCI. *N Engl J Med*, 361(24), 2318-2329, doi:10.1056/NEJMoa0908628.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
25. Angiolillo, D. J., Rollini, F., Storey, R. F., Bhatt, D. L., James, S., Schneider, D. J., et al. (2017). International Expert Consensus on Switching Platelet P2Y12 Receptor-Inhibiting Therapies. *Circulation*, *136*(20), 1955-1975, doi:10.1161/CIRCULATIONAHA.117.031164.
 26. Franchi, F., Rollini, F., Rivas, A., Wali, M., Briceno, M., Agarwal, M., et al. (2019). Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Circulation*, *139*(14), 1661-1670, doi:10.1161/CIRCULATIONAHA.118.038317.
 27. Vaduganathan, M., Harrington, R. A., Stone, G. W., Deliargyris, E. N., Steg, P. G., Gibson, C. M., et al. (2017). Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. *JAMA Cardiol*, *2*(2), 127-135, doi:10.1001/jamacardio.2016.4556.
 28. Sibbing, D., Aradi, D., Alexopoulos, D., Ten Berg, J., Bhatt, D. L., Bonello, L., et al. (2019). Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. *JACC Cardiovasc Interv*, *12*(16), 1521-1537, doi:10.1016/j.jcin.2019.03.034.
 29. Sibbing, D., Braun, S., Morath, T., Mehilli, J., Vogt, W., Schomig, A., et al. (2009). Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. *J Am Coll Cardiol*, *53*(10), 849-856, doi:10.1016/j.jacc.2008.11.030.
 30. Farid, N. A., McIntosh, M., Garofolo, F., Wong, E., Shwajch, A., Kennedy, M., et al. (2007). Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. *Rapid Commun Mass Spectrom*, *21*(2), 169-179, doi:10.1002/rcm.2813.
 31. Bulluck, H., Dharmakumar, R., Arai, A. E., Berry, C., & Hausenloy, D. J. (2018). Cardiovascular Magnetic Resonance in Acute ST-Segment-Elevation Myocardial Infarction: Recent Advances, Controversies, and Future Directions. *Circulation*, *137*(18), 1949-1964, doi:10.1161/CIRCULATIONAHA.117.030693.
 32. Ibanez, B., Aletras, A. H., Arai, A. E., Arheden, H., Bax, J., Berry, C., et al. (2019). Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel. *J Am Coll Cardiol*, *74*(2), 238-256, doi:10.1016/j.jacc.2019.05.024.
 33. Gragnano, F., Spedicato, V., Frigoli, E., Gargiulo, G., Di Maio, D., Fimiani, F., et al. (2019). ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. *J Electrocardiol*, *57*, 44-54, doi:10.1016/j.jelectrocard.2019.08.045.

Figure Legend

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1. Design of the FABOLUS-FASTER study.

Figure 2. Procedures of the FABOLUS-FASTER study.

Table 1. Inclusion and exclusion criteria of the FABOLUS-FASTER study.

INCLUSION CRITERIA	
•	Signed Informed Consent
•	Age greater than 18 years old
•	Have symptoms of acute myocardial ischemia (i.e. new persistent anginal pain) that were lasting at least 20 min with an electrocardiographic ST-segment elevation > 1 mm in 2 or more contiguous ECG leads, or with a new (or presumably new) left bundle branch block or ST segment depression of ≥1 mm in ≥2 of leads V1-3 with a positive terminal T wave
•	Referred for primary PCI either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia
EXCLUSION CRITERIA	
•	Unconsciousness
•	Other conditions that make the patient incapable receiving integer loading dose of prasugrel
•	Any contraindication and/or known hypersensitivity or allergy to aspirin, prasugrel, intravenous unfractionated heparin, cangrelor, tirofiban
•	Any contraindication to primary PCI
•	Administration of GPI or P2Y12-inhibitors or cangrelor < 7 days
•	Chronic dialysis
•	Recent (< 15 days) or current major bleeding
•	Recent (< 15 days) major surgery
•	Administration of fibrinolytics < 30 days
•	Current use or indication to oral anticoagulant
•	Previous stroke or TIA
•	Inability to follow the procedures of the study (language problems, psychological disorders, dementia) or comorbidities associated with less than 6 months survival (active malignancies drug or alcohol abuse, etc.)
•	Women who are pregnant or breast feeding or with potential to become pregnant during the course of the study (age < 55 years and last menstruation within the last 12 months) and did not undergo tubal ligation, ovariectomy or hysterectomy
•	Participation in another study with investigational drug within the 30 days preceding and during the present study
•	Enrolment of the investigator, his/her family members, employees and other dependent persons



